268
Views
14
CrossRef citations to date
0
Altmetric
Drug Profile

The efficacy and safety of inhaled human α-1 antitrypsin in people with α-1 antitrypsin deficiency-related emphysema

, &

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Ilaria Ferrarotti, Angelo Guido Corsico, Jan Stolk, Stefania Ottaviani, Marco Fumagalli, Sabina Janciauskiene & Paolo Iadarola. (2017) Advances in Identifying Urine/Serum Biomarkers in Alpha-1 Antitrypsin Deficiency for More Personalized Future Treatment Strategies. COPD: Journal of Chronic Obstructive Pulmonary Disease 14:1, pages 56-65.
Read now

Articles from other publishers (13)

Annalisa Bianchera, Viviana Vilardo, Roberta Giaccari, Annalisa Michielon, Gianluca Bazzoli, Francesca Buttini, Marina Aiello, Alfredo Chetta, Stefano Bruno & Ruggero Bettini. (2023) Nebulizers effectiveness on pulmonary delivery of alpha-1 antitrypsin. Drug Delivery and Translational Research.
Crossref
Michael Troy, Joseph Van Vleet, Donald Tashkin & Igor Barjaktarevic. (2023) Recent advances predict a bright future for nebulizers. Current Opinion in Pulmonary Medicine 29:2, pages 123-132.
Crossref
Alon Gimmon, Lior Sherker, Lena Kojukarov, Melodie Zaknoun, Yotam Lior, Tova Fadel, Ronen Schuster, Eli C. Lewis & Eldad Silberstein. (2022) Accelerated Wound Border Closure Using a Microemulsion Containing Non-Inhibitory Recombinant α1-Antitrypsin. International Journal of Molecular Sciences 23:13, pages 7364.
Crossref
Anna Gorący, Jakub Rosik, Bartosz Szostak, Łukasz Ustianowski, Klaudia Ustianowska & Jarosław Gorący. (2022) Human Cell Organelles in SARS-CoV-2 Infection: An Up-to-Date Overview. Viruses 14:5, pages 1092.
Crossref
Lukas Wettstein, Frank Kirchhoff & Jan Münch. (2022) The Transmembrane Protease TMPRSS2 as a Therapeutic Target for COVID-19 Treatment. International Journal of Molecular Sciences 23:3, pages 1351.
Crossref
Xiao Liu, Kevin Vanvarenberg, Kobenan Guy Wilfried Kouassi, Sohaib Mahri & Rita Vanbever. (2022) Production and characterization of mono-PEGylated alpha-1 antitrypsin for augmentation therapy. International Journal of Pharmaceutics 612, pages 121355.
Crossref
Sean D. McCarthy, Héctor E. González & Brendan D. Higgins. (2020) Future Trends in Nebulized Therapies for Pulmonary Disease. Journal of Personalized Medicine 10:2, pages 37.
Crossref
Cláudia Henrique da Costa, Arnaldo José Noronha Filho, Rosa Maria Fernambel Marques e Silva, Thaís Ferrari da Cruz, Valeria de Oliveira Monteiro, Margareth Pio & Rogério Lopes Rufino. (2019) Alpha 1-antitrypsin deficiency in patients with chronic obstructive pulmonary disease patients: is systematic screening necessary?. BMC Research Notes 12:1.
Crossref
Jan Stolk, Naveh Tov, Kenneth R. Chapman, Pablo Fernandez, William MacNee, Nicholas S. Hopkinson, Eeva Piitulainen, Niels Seersholm, Claus F. Vogelmeier, Robert Bals, Gerry McElvaney & Robert A. Stockley. (2019) Efficacy and safety of inhaled α1-antitrypsin in patients with severe α1-antitrypsin deficiency and frequent exacerbations of COPD. European Respiratory Journal 54:5, pages 1900673.
Crossref
Irina Petrache. (2019) Is More Better? Promising Biological Effects of Double-Dose Alpha 1-Antitrypsin Therapy. American Journal of Respiratory and Critical Care Medicine 200:3, pages 270-272.
Crossref
Ignacio Blanco. 2017. Blanco's Overview of Alpha-1 Antitrypsin Deficiency. Blanco's Overview of Alpha-1 Antitrypsin Deficiency 207 225 .
Cormac McCarthy, Emer P. Reeves & Noel G. McElvaney. (2016) The Role of Neutrophils in Alpha-1 Antitrypsin Deficiency. Annals of the American Thoracic Society 13:Supplement_4, pages S297-S304.
Crossref
Catherine M. Greene, Stefan J. Marciniak, Jeffrey Teckman, Ilaria Ferrarotti, Mark L. Brantly, David A. Lomas, James K. Stoller & Noel G. McElvaney. (2016) α1-Antitrypsin deficiency. Nature Reviews Disease Primers 2:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.